glp 1 oral medicine New GLP-1 Guidelines for Type 2 Diabetes in 2025 FDA approves Foundayo, an oral

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating

This strategic move is likely to enhance the efficiency of clinical trials and accelerate the time-to-market for new therapies

Med Sci Monit 23:54105419 Sun HX, Lu N, Luo X, Zhao L, Liu JM (2015) Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats

By activating GIP receptors, GIP agonists can enhance insulin secretion and lower blood sugar levels

The pharmaceutical industry expects significant market disruption once generic alternatives receive Health Canada approval, potentially in summer 2026

PlexusDx maintains continuous pharmacist and provider oversight, adjusting dosing protocols based on your response and any side effects you report